Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Completed 95 enrolled AstraZeneca

Non-randomizedParallel-groupOpen-labelTreatment

Adavosertib in combination with carboplatin, paclitaxel, gemcitabine, or PLD.

Evaluation	Drug	Modality	Dose	Route
Subject	Adavosertib	Small molecule	175 mg	Oral
Subject	Adavosertib	Small molecule	225 mg	Oral
Subject	Carboplatin	Small molecule	5 unknown	Intravenous
Subject	Gemcitabine	Small molecule	800 mg/m2	Intravenous
Subject	Paclitaxel	Small molecule	80 mg/m2	Intravenous
Subject	pegylated liposomal doxorubicin	Unknown	40 mg/m2	Intravenous